2011
Category: Development History
Release Date: 2023-01-05
Summary: The company was recognized as the “Hubei Provincial Cardiovascular Drug Research and Development Center.” In the same year, five projects received special funding under the national “Major New Drug Creation” program, and the “Qirui International Integrated Innovation Drug Incubation Base” was approved; additionally, the “Hubei Provincial Biopharmaceutical Graduate Education Innovation Base” was established.
The company was recognized as the “Hubei Provincial Cardiovascular Drug Research and Development Center.” In the same year, five projects received special funding under the national “Major New Drug Creation” program, and the “Qirui International Integrated Innovation Drug Incubation Base” was approved; additionally, the “Hubei Provincial Biopharmaceutical Graduate Education Innovation Base” was established.
Keywords: 2011
Related News Centers
Academic Column
Development History
-
2019
Release time:2023-01-05
-
2018
Release time:2023-01-05
-
2017
Release time:2023-01-05
-
2014
Release time:2023-01-05
-
2013
Release time:2023-01-05
-
2012
Release time:2023-01-05
-
2011
Release time:2023-01-05
-
2010
Release time:2023-01-05
-
2009
Release time:2023-01-05
-
2008
Release time:2023-01-05
-
2007
Release time:2023-01-05
-
2006
Release time:2023-01-05
-
2005
Release time:2023-01-05
-
2004
Release time:2022-12-30
-
2003
Release time:2022-12-30
Branch office
News and Information
-
Qirui Group’s First Innovative Drug, MY008211A Tablets (Lanocapam Hydrochloride Tablets), Successfully Achieves the Primary Efficacy Endpoint in Phase III Clinical Trials
Release time:2026-02-25
-
Qirui Group’s First Innovative Drug Passes Both National Key Inspections on the First Attempt
Release time:2026-01-27
-
Three Employees of Qirui Pharmaceutical Awarded Jiangxia District’s Tangxun Lake Talent Recognition!
Release time:2026-01-15
-
“A ‘Start’ That Stands Out, Bringing in Talented Young Professionals — Qirui Group’s 2026 Campus Recruitment Concludes Successfully”
Release time:2025-12-31
-
Qirui Pharmaceutical’s Ganyining® Ademetionine Disulfonate for Injection Wins Bid in the 11th National Centralized Procurement Round
Release time:2025-11-11
-
Qirui Group Makes Its Debut at the 17th Bio-Industry Conference
Release time:2025-09-08
-
Empowering Your Journey, Illuminating the Path Ahead—Qirui Group’s 2025 New Graduate Onboarding Program Concludes Successfully
Release time:2025-07-23
-
Internationally Accredited! Qirui Technology Earns ACCA Recognized Employer Status
Release time:2025-07-08
-
Safeguarding the Source of Life and Fortifying the Quality Defense Line for Pharmaceutical Water — Professional Training on Purified Water Systems at Qirui Pharmaceutical
Release time:2025-06-05
-
Wuhan Qirui Technology Development Co., Ltd. Donates RMB 100 Million to Huazhong University of Science and Technology
Release time:2025-03-17
-
People-Oriented, Win-Win Future | Qirui Pharmaceutical Honored as “2024 China’s Top Employer”
Release time:2025-02-18
-
Empowering Party Building to Unite New Forces, Achieve Synergy, and Expand “Health”
Release time:2024-07-10
-
Qirui Group Makes Its Debut at CPHI China 2024
Release time:2024-06-28
-
Enhancing Competence Through Competition and Pursuing Development Through Quality: Qirui Pharmaceutical Successfully Holds Its 2024 Annual Quality Knowledge Competition
Release time:2024-06-28
-
Shining with the Light of Wisdom, Passing on the Torch of Scholarship — The Joint Master’s Thesis Defense Ceremony between Qirui Pharmaceutical and China Pharmaceutical University Concludes Successfully
Release time:2024-06-07
-
Academic Gala | The 8th International Forum on Drug-Induced Liver Injury Concludes Successfully; Ornithine Aspartate Recommended in the “Chinese Guidelines for Primary Care Diagnosis and Management of Drug-Induced Liver Injury (2024)”
Release time:2024-05-31
-
Qirui Pharmaceutical Awarded the “Wuhan May Day Labor Medal”
Release time:2024-05-13
-
Qirui Pharmaceutical Selected for Inclusion in the 2023 Jiangxia District List of Proposed Projects for District-Level Technology Transfer and Key R&D Initiatives
Release time:2024-04-12
-
“Made in Wuhan” Generic Drugs Added to the 2020 National Reimbursement Drug List
Release time:2021-03-05
-
Congratulatory Letter to Shandong Ruiyin Bioengineering Co., Ltd.
Release time:2021-02-01
-
Douyin Live Stream Coverage | Qirui’s 2020 Annual Work Summary and Awards Ceremony Held Successfully!
Release time:2021-01-28
-
First Public Notice of the Environmental Impact Assessment for the Demonstration Project on the Transformation and Construction of a Multi-Functional, Intelligent, Safe, Green, and High-End Active Pharmaceutical Ingredient Production Platform and Pilot-Scale Service Platform at Wuhan Zhongyou Pharmaceutical Co., Ltd.
Release time:2020-06-28
-
Decision on Commending the 2020 Pioneers in Epidemic Prevention Responsibility and Model Workers in Resuming Work and Production
Release time:2020-05-11
-
Notice of the Renewal of the Employee Care and Corporate Culture Development Committee
Release time:2020-04-27
Sunshine Avenue, Sunshine Third Road, Miaoshan Subdistrict, Economic Development Zone, Jiangxia District, Wuhan, Hubei Province
QR code
Copyright © Wuhan Qirui Pharmaceutical Co., Ltd. |Privacy Policy
Powered by www.300.cn
This website supports IPv6.